Popular on Rezul
- No Limits Method Revolutionizes Neurodivergent Education Through Embodied Cognition - 107
- Corner Property Management Welcomes Seneca Reserve HOA! - 104
- Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
- First AI Marketing Platform Built Specifically for Small Businesses Launches Public Beta
- TEDxInglewood Returns to The Miracle Theater on August 9, 2025 — Celebrating Bold Ideas and Community Energy
- Rediscovered Christopher Lee Recording 'Elenore' Re-Released to Mark 10th Anniversary of His Passing
- Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach
- Conexwest Expands Single-Phase Cold Storage Lineup: Versatile Solutions for Diverse Temperature Needs
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
Similar on Rezul
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
Long-term results with the Tat vaccine point to a new approach for a functional cure of HIV
Rezul News/10408921
ROME, Italy - Feb. 16, 2019 - Rezul -- A new study announced by Istituto Superiore di Sanità (ISS, Rome, Italy) and published in "Frontiers in Immunology, February 13, 2019" suggests new avenues toward cure of HIV: the administration of the recombinant HIV-1 Tat protein (rTAT) to people living with HIV on antiretroviral therapy drastically reduced the "latent virus reservoir", which is invulnerable to HIV drugs. The rTAT has been developed at the National HIV/AIDS Research Center of the Istituto Superiore di Sanità (Rome, Italy), under the leadership of its Director, Dr Barbara Ensoli.
The results announced by ISS open new perspectives for a "functional" cure of HIV, i.e. the ability to control the virus during the suspension of antiretroviral drugs; a functional cure would ease the long-term clinical management of people with HIV by reducing the cumulative toxicity of antiretroviral drugs while improving adherence to therapy and quality of life that are crucial especially for children and adolescents.
Almost 40 years from the discovery of the virus, HIV/AIDS remains a global emergency, particularly for the poorest and most vulnerable populations in the world: women and children, homosexuals, bisexuals and transgenders (LGBT), sex workers, migrants, and users of injectable drugs. To date, almost 40 million people in the world live with HIV infection, half of them without any treatment, and international agencies are calling for a renewed effort, more investments and innovative strategies to find a cure for HIV and eradicate the virus.
More on Rezul News
Strict adherence to lifelong therapy is required to control HIV, in fact the virus hides in the "virus reservoir" as silent viral DNA invisible to the immune system and to antiretroviral therapy (ART), but it reactivates once therapy is interrupted. In the new study entitled "Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on long-term ART: an 8-year follow-up study", published in the open access journal "Frontiers in Immunology", February 13, the authors present data of the long-term clinical monitoring of 92 volunteers who completed the previous phase II clinical trial in Italy (ISS T-002 ClinicalTrials.gov NCT00751595) and enrolled in the extended follow-up (ISS T-002 EF-UP, ClinicalTrials.gov NCT02118168). The 8-year study was conducted in 8 clinical sites in Italy: San Raffaele Hospital in Milan, L. Sacco Hospital of the University of Milan, San Gerardo Hospital in Monza, University Hospital of Ferrara, Policlinic Hospital of the University of Modena, Santa Maria Annunziata Hospital in Florence, San Gallicano Dermatological Institute in Rome, and the Policlinic Hospital in Bari. The results suggest new avenues towards a "functional cure" and, in perspective, the eradication of HIV.
The study shows that the volunteers treated with rTAT after being on ART for an average of 6 years, experienced, during the following 8 years, a continued decrease of viral DNA in blood, which occurred at an average speed 4-7 times greater than that observed in similar studies in patients treated with ART alone. Furthermore, in the vaccinated volunteers the reduction of the virus reservoir was associated with an increase in CD4+ T-cell number and CD4+/CD8+ T-cell ratio. A very small reservoir of latent virus (as evidenced by the low levels of proviral DNA in blood), and a good recovery of the immune system (as indicated by a high ratio of CD4+/CD8+ T lymphocytes) are found also in rare patients called "post-treatment controllers", who can control the reactivation of HIV after discontinuing therapy.
More on Rezul News
It is therefore conceivable that vaccination with Tat may confer to patients the ability to become post-treatment controllers, i.e. to control the virus without taking medications for periods of time the duration of which will be evaluated with specific clinical studies. Therefore, the results of the study lead to programmed and controlled therapy interruptions in volunteers treated with ART and rTAT that are currently being planned in order to verify this hypothesis.
The economic impact of a HIV cure is expected to be substantial. HIV is taking vast resources from the fight against poverty and inequality in the world: $ 563 billion between 2000 and 2015, a taxpayer contribution of $ 100 dollars in developing countries and $ 5,000 in Europe and North America ($ 330/$ year); and a net loss of national wealth (GDP) in African countries of between - $ 30 - $ 150 billion a year ($450 billion -4.5 trillion in 15 years), huge figures that impose urgent and innovative therapeutic solutions for HIV/AIDS.
For more information visit http://www.vaxxit.com
The results announced by ISS open new perspectives for a "functional" cure of HIV, i.e. the ability to control the virus during the suspension of antiretroviral drugs; a functional cure would ease the long-term clinical management of people with HIV by reducing the cumulative toxicity of antiretroviral drugs while improving adherence to therapy and quality of life that are crucial especially for children and adolescents.
Almost 40 years from the discovery of the virus, HIV/AIDS remains a global emergency, particularly for the poorest and most vulnerable populations in the world: women and children, homosexuals, bisexuals and transgenders (LGBT), sex workers, migrants, and users of injectable drugs. To date, almost 40 million people in the world live with HIV infection, half of them without any treatment, and international agencies are calling for a renewed effort, more investments and innovative strategies to find a cure for HIV and eradicate the virus.
More on Rezul News
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- Walnut Hills Launches Off-Grid Hempcrete Homes and Eco-Retreat in Western NC
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
Strict adherence to lifelong therapy is required to control HIV, in fact the virus hides in the "virus reservoir" as silent viral DNA invisible to the immune system and to antiretroviral therapy (ART), but it reactivates once therapy is interrupted. In the new study entitled "Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on long-term ART: an 8-year follow-up study", published in the open access journal "Frontiers in Immunology", February 13, the authors present data of the long-term clinical monitoring of 92 volunteers who completed the previous phase II clinical trial in Italy (ISS T-002 ClinicalTrials.gov NCT00751595) and enrolled in the extended follow-up (ISS T-002 EF-UP, ClinicalTrials.gov NCT02118168). The 8-year study was conducted in 8 clinical sites in Italy: San Raffaele Hospital in Milan, L. Sacco Hospital of the University of Milan, San Gerardo Hospital in Monza, University Hospital of Ferrara, Policlinic Hospital of the University of Modena, Santa Maria Annunziata Hospital in Florence, San Gallicano Dermatological Institute in Rome, and the Policlinic Hospital in Bari. The results suggest new avenues towards a "functional cure" and, in perspective, the eradication of HIV.
The study shows that the volunteers treated with rTAT after being on ART for an average of 6 years, experienced, during the following 8 years, a continued decrease of viral DNA in blood, which occurred at an average speed 4-7 times greater than that observed in similar studies in patients treated with ART alone. Furthermore, in the vaccinated volunteers the reduction of the virus reservoir was associated with an increase in CD4+ T-cell number and CD4+/CD8+ T-cell ratio. A very small reservoir of latent virus (as evidenced by the low levels of proviral DNA in blood), and a good recovery of the immune system (as indicated by a high ratio of CD4+/CD8+ T lymphocytes) are found also in rare patients called "post-treatment controllers", who can control the reactivation of HIV after discontinuing therapy.
More on Rezul News
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Nevada Real Estate Agent David Crane Helping Families Find Their Dream Home
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
It is therefore conceivable that vaccination with Tat may confer to patients the ability to become post-treatment controllers, i.e. to control the virus without taking medications for periods of time the duration of which will be evaluated with specific clinical studies. Therefore, the results of the study lead to programmed and controlled therapy interruptions in volunteers treated with ART and rTAT that are currently being planned in order to verify this hypothesis.
The economic impact of a HIV cure is expected to be substantial. HIV is taking vast resources from the fight against poverty and inequality in the world: $ 563 billion between 2000 and 2015, a taxpayer contribution of $ 100 dollars in developing countries and $ 5,000 in Europe and North America ($ 330/$ year); and a net loss of national wealth (GDP) in African countries of between - $ 30 - $ 150 billion a year ($450 billion -4.5 trillion in 15 years), huge figures that impose urgent and innovative therapeutic solutions for HIV/AIDS.
For more information visit http://www.vaxxit.com
Source: Vaxxit
Filed Under: Investment
0 Comments
Latest on Rezul News
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- Dedeaux Properties Begins Construction on Truck Terminal and Industrial Outdoor Storage Facility
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- Paulding County's Old Mill Preserve Now Open to the Public in Georgia
- Kramer Real Estate: The Boutique Brokerage Quietly Taking Over North Texas
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Salazar Heating, Cooling & Plumbing Launches Water Conservation Initiative to Help Santa Fe Homeowners Cut Water Waste
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Winners Development Corporation Pioneers Skyscraper In South Dallas
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Extreme Exterior Cleaning of Seaside Florida Home Separates Pros from Amateurs
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)